Searched for
BIOSIMILAR INSULIN GLARGINE
Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...30 Nov, 2023, 07.30 PM IST- 'Biocon Biologics to integrate Viatris' US biosimilar business by Q2 end'Biocon Biologics plans to complete the integration of Viatris' biosimilar business in North America by the end of Q2FY24, which is ahead of...14 Aug, 2023, 11.46 PM IST
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...22 Jan, 2022, 04.07 PM IST
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...19 Nov, 2021, 04.12 PM IST
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...21 Oct, 2021, 10.30 AM IST
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...30 Jul, 2021, 06.49 PM IST
- Biocon Biologics launches Semglee, drug to control high blood sugar, in USTo encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...31 Aug, 2020, 05.11 PM IST
- Biocon, Mylan launch insulin biosimilar in AustraliaThe biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.03 Oct, 2019, 03.18 PM IST
- Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...22 Aug, 2019, 03.09 PM IST
- Biocon teams up with Swiss drugmaker Sandoz for next gen biosimilarUnder the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...19 Jan, 2018, 01.38 PM IST
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.03 Nov, 2016, 08.48 PM IST
- Biocon's partner firm launches diabetes product in JapanIn March this year, Biocon received approval from the Japanese health authority to sell its biosimilar product Insulin Glargine.15 Jul, 2016, 12.52 PM IST
- Biocon's biosimilars progressAnalysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...29 Apr, 2016, 12.47 PM IST
- Approval for insulin biosimilar in Japan a milestone for Biocon: Kiran Mazumdar Shaw, BioconThis will also help Biocon enter the US and European markets in the near future29 Mar, 2016, 08.28 AM IST
- Biocon gets nod to sell its diabetes product 'Insulin Glargine' in JapanBiocon has received approval from the Japanese health authority to sell its biosimilar product 'Insulin Glargine' in that country.28 Mar, 2016, 04.08 PM IST
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...22 Oct, 2015, 03.47 PM IST
- Pfizer deal shot in arm for BioconAs per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...20 Oct, 2010, 12.55 AM IST
Load More
